218 related articles for article (PubMed ID: 29516607)
1. Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice.
Jung HY; Kim B; Ryu HG; Ji Y; Park S; Choi SH; Lee D; Lee IK; Kim M; Lee YJ; Song W; Lee YH; Choi HJ; Hyun CK; Holzapfel WH; Kim KT
Diabetes Obes Metab; 2018 Jul; 20(7):1688-1701. PubMed ID: 29516607
[TBL] [Abstract][Full Text] [Related]
2. A nonthiazolidinedione peroxisome proliferator-activated receptor α/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice.
Jeong HW; Lee JW; Kim WS; Choe SS; Shin HJ; Lee GY; Shin D; Lee JH; Choi EB; Lee HK; Yon GH; Cho B; Kim HR; Choi SH; Chung YS; Park SB; Chung H; Ro S; Kim JB
Mol Pharmacol; 2010 Nov; 78(5):877-85. PubMed ID: 20724462
[TBL] [Abstract][Full Text] [Related]
3. A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.
Jeong HW; Lee JW; Kim WS; Choe SS; Kim KH; Park HS; Shin HJ; Lee GY; Shin D; Lee H; Lee JH; Choi EB; Lee HK; Chung H; Park SB; Park KS; Kim HS; Ro S; Kim JB
Diabetes; 2011 Feb; 60(2):496-506. PubMed ID: 21270261
[TBL] [Abstract][Full Text] [Related]
4. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
[TBL] [Abstract][Full Text] [Related]
5. MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism.
Kim SH; Hong SH; Park YJ; Sung JH; Suh W; Lee KW; Jung K; Lim C; Kim JH; Kim H; Park KS; Park SG
Sci Rep; 2019 Feb; 9(1):1656. PubMed ID: 30733541
[TBL] [Abstract][Full Text] [Related]
6. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
7. Anti-diabetic effect of amorphastilbol through PPARα/γ dual activation in db/db mice.
Lee W; Ham J; Kwon HC; Kim YK; Kim SN
Biochem Biophys Res Commun; 2013 Mar; 432(1):73-9. PubMed ID: 23376064
[TBL] [Abstract][Full Text] [Related]
8. C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
Xu C; Wang LL; Liu HY; Zhou XB; Cao YL; Li S
Acta Pharmacol Sin; 2006 Feb; 27(2):223-8. PubMed ID: 16412273
[TBL] [Abstract][Full Text] [Related]
9. P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice.
Chen W; Zhou XB; Liu HY; Xu C; Wang LL; Li S
Br J Pharmacol; 2009 Jul; 157(5):724-35. PubMed ID: 19422369
[TBL] [Abstract][Full Text] [Related]
10. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
[TBL] [Abstract][Full Text] [Related]
11. A novel PPARα/γ agonist, propane-2-sulfonic acid octadec-9-enyl-amide, ameliorates insulin resistance and gluconeogenesis in vivo and vitro.
Ren T; Yang WS; Lin Y; Liu JF; Li Y; Yang LC; Zeng KY; Peng L; Liu YJ; Ye ZH; Luo XM; Ke YJ; Diao Y; Jin X
Eur J Pharmacol; 2018 May; 826():1-8. PubMed ID: 29476879
[TBL] [Abstract][Full Text] [Related]
12. A Novel Peroxisome Proliferator-activated Receptor (PPAR)α Agonist and PPARγ Antagonist, Z-551, Ameliorates High-fat Diet-induced Obesity and Metabolic Disorders in Mice.
Shiomi Y; Yamauchi T; Iwabu M; Okada-Iwabu M; Nakayama R; Orikawa Y; Yoshioka Y; Tanaka K; Ueki K; Kadowaki T
J Biol Chem; 2015 Jun; 290(23):14567-81. PubMed ID: 25907553
[TBL] [Abstract][Full Text] [Related]
13. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
[TBL] [Abstract][Full Text] [Related]
15. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Laurent D; Gounarides JS; Gao J; Boettcher BR
Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
[TBL] [Abstract][Full Text] [Related]
16. A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease.
Sahin C; Melanson JR; Le Billan F; Magomedova L; Ferreira TAM; Oliveira AS; Pollock-Tahari E; Saikali MF; Cash SB; Woo M; Romeiro LAS; Cummins CL
Mol Metab; 2024 Jul; 85():101958. PubMed ID: 38763495
[TBL] [Abstract][Full Text] [Related]
17. Cevoglitazar, a novel peroxisome proliferator-activated receptor-alpha/gamma dual agonist, potently reduces food intake and body weight in obese mice and cynomolgus monkeys.
Chen H; Dardik B; Qiu L; Ren X; Caplan SL; Burkey B; Boettcher BR; Gromada J
Endocrinology; 2010 Jul; 151(7):3115-24. PubMed ID: 20484464
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
[TBL] [Abstract][Full Text] [Related]
19. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
[TBL] [Abstract][Full Text] [Related]
20. Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.
Gao M; Bu L; Ma Y; Liu D
PLoS One; 2013; 8(6):e65641. PubMed ID: 23762402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]